Navigation Links
Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
Date:12/9/2010

BEIJING, Dec. 9, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced that it plans to sell or transfer approximately 165 acres (1,000 MU) of Company-owned land in the Chahaer Industrial Park, Inner Mongolia. Lotus' operating entity, Beijing Liang Fang Pharmaceutical Co., Ltd., purchased the land-use rights for the property in 2008. Lotus had originally intended to build a pharmaceutical manufacturing and storage facility on a portion of the property.

In March 2010, Lotus began construction on a 250,000-square-foot facility in Beijing after receiving permission from the Beijing Chaoyang District Planning Bureau. The new building will house the Company's R&D center, manufacturing operations, storage facilities, sales and administrative offices. The building will become Lotus' new corporate headquarters following its completion. Management expects to move into the building by June 2011.

Lotus' Chairman and CEO, Mr. Zhongyi Liu, stated, "We have decided not to move forward with the construction of our planned facility in Inner Mongolia in order to focus our efforts and resources on expanding our core business in Beijing. We believe that selling or transferring this property will be a more effective use of our capital."

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Tel: 415-690-7688Email: shen@lotuspharma.comWeb: http://www.lotuspharma.comInvestor Relations:Dave GentryRedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 104Email: info@redchip.comWeb: http://www.redchip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
4. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
5. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
6. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
7. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
8. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
9. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
10. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
11. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the rise for ... as an orthogonal tool for RNAi hit validation. A key reason may be that ... rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed ...
(Date:5/31/2016)... ... 31, 2016 , ... In a recent interview on The Greenburgh Report radio ... NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed ... medical money maelstrom.” , During the interview with Mr. Feiner that aired on ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising ... firm and statement solutions provider, for the tenth consecutive year as a Top ... of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” ...
(Date:5/31/2016)... Port Washington, NY (PRWEB) , ... May 31, 2016 , ... ... and other essential nutrients to on the go individuals and dedicated athletes, continues to ... functions. , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... announced today the publication of an original infographic, " Health Benefits Reimbursement Compliance ... professionals understand how Zane Benefits complies with various federal regulations and reforms. , ...
Breaking Medicine News(10 mins):